Top

Published in:

Open Access 02-12-2023 | Generalized Pustular Psoriasis | Commentary

Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice

Authors: Anna Balato, Francesca Ambrogio, Martina Burlando, Carlo Giovanni Carrera, Andrea Chiricozzi, Maria Esposito, Stefano Piaserico, Miriam Teoli, Paolo Gisondi

Published in: Dermatology and Therapy | Issue 1/2024

Excerpt

Generalized pustular psoriasis (GPP) is a rare, severe skin condition with recurrent pustules and unpredictable flares, causing discomfort and potentially life-threatening complications.

Compared to patients with plaque psoriasis, patients with GPP have a higher burden of illness and suffer from increased psychological distress.

Unmet needs in GPP management include limited awareness, misdiagnosis, and the lack of guidelines for treatment selection.

Raising awareness, educating patients, and streamlining the patient journey can optimize GPP management.

Introduction of novel therapies, like spesolimab, offers hope for effective treatment, potentially reducing mortality and hospitalization.

…

Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239–52. https://doi.org/10.1080/1744666X.2019.1708193.CrossRefPubMed

Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–19. https://doi.org/10.1080/1744666X.2019.1648209.CrossRefPubMed

Strober B, Kotowsky N, Medeiros R, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529–41. https://doi.org/10.1007/s13555-021-00493-0.CrossRefPubMed

Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42. https://doi.org/10.2147/PTT.S181808.CrossRefPubMed

Umezawa Y, Ozawa A, Kawasima T, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295(Suppl 1):S43-54.CrossRefPubMed

Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. https://doi.org/10.1111/jdv.14386

Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–70.CrossRefPubMed

Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–88.CrossRefPubMed

Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382–8.CrossRefPubMed

10.

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J. Systemic monotherapy treatments for generalized pustular psoriasis: a systematic review. J Cutan Med Surg. 2018;22(6):591–601.CrossRefPubMed

11.

David M, Hodak E, Lowe NJ. Adverse effects of retinoids. Med Toxicol Adverse Drug Exp. 1988;3(4):273–88.PubMed

12.

Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–3.CrossRefPubMed

13.

Maçães CO, Lé AM, Torres T. Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. J Dermatolog Treat. 2022;33(7):2911–8. https://doi.org/10.1080/09546634.2022.2089335.CrossRefPubMed

14.

Crowley J, Golembesky AK, Menter A, et al. Clinical characteristics and healthcare resource utilization in patients with generalized pustular psoriasis: real-world evidence from a large claims-based dataset. J Psoriasis Psoriatic Arthritis. 2021;6(3):151–8.CrossRef

15.

Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor. Malaysia Int J Dermatol. 2014;53:676–84.CrossRefPubMed

16.

Wang HM, Xu JM, Jin HZ. Characteristics and burdens of disease in patients from Beijing with generalized pustular psoriasis and palmoplantar pustulosis: multicenter retrospective cohort study using a regional database. Am J Clin Dermatol. 2023. https://doi.org/10.1007/s40257-023-00807-2.CrossRefPubMed

17.

Ericson O, Löfvendahl S, Norlin JM, Gyllensvard H, Schmitt-Egenolf M. Mortality in generalized pustular psoriasis: a population-based national register study. J Am Acad Dermatol. 2023;S0190–9622(23):00978–87. https://doi.org/10.1016/j.jaad.2023.04.066.CrossRef

18.

Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023;13(3):673–88. https://doi.org/10.1007/s13555-022-00881-0.CrossRefPubMed

19.

Choon SE, Wright AK, Griffiths CEM, et al. Global Psoriasis Atlas. Incidence and prevalence of generalised pustular psoriasis in multi-ethnic Johor Bahru, Malaysia: a population-based cohort study using routinely captured electronic health records in Teleprimary Care (TPC®) clinical information system from 2010 to 2020. Br J Dermatol. 2023:ljad158. https://doi.org/10.1093/bjd/ljad158.

20.

Feng JN, Guo JZ, Zhang Q, et al. Higher prevalence of generalized pustular psoriasis in asia? A population-based study using claim data in China and a systematic review. Dermatology. 2023;239(2):195–205. https://doi.org/10.1159/000528850.CrossRefPubMed

21.

Montero-Vilchez T, Grau-Perez M, Garcia-Doval I. Epidemiology and geographic distribution of generalized pustular psoriasis in Spain: a national population-based study of hospital admissions from 2016 to 2020. Actas Dermosifiliogr. 2023;114(2):T97–101. https://doi.org/10.1016/j.ad.2022.09.020.CrossRef

22.

Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study. J Am Acad Dermatol. 2023;88(3):736–8. https://doi.org/10.1016/j.jaad.2022.09.049.CrossRefPubMed

23.

Mastacouris N, Feda A, Strunk A, Garg A. Risk factors for generalized pustular psoriasis: a case-control study. J Am Acad Dermatol. 2023;S0190–9622(23):01169–76. https://doi.org/10.1016/j.jaad.2023.06.018.CrossRef

24.

Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48(11):1675–87. https://doi.org/10.1111/1346-8138.16084.CrossRefPubMedPubMedCentral

25.

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. J Dermatol Treat. 2021;32(5):492–4.CrossRef

26.

Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.CrossRefPubMed

27.

Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109–20.CrossRefPubMed

28.

Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133:2514–21.CrossRefPubMed

29.

Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–40.CrossRefPubMed

30.

Blair HA. Spesolimab: first approval. Drugs. 2022;82:1681–6.CrossRefPubMedPubMedCentral

31.

Morita A, Tsai TF, Yee EYW, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study. J Dermatol. 2023;50(2):183–94. https://doi.org/10.1111/1346-8138.16609.CrossRefPubMed

32.

Morita A, Choon SE, Bachelez H, et al. Design of Effisayil™ 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther (Heidelb). 2023;13(1):347–59. https://doi.org/10.1007/s13555-022-00835-6.CrossRefPubMed

33.

Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of generalized pustular psoriasis from the per-spective of people living with the condition: results of an online survey. Am J Clin Dermatol. 2022;23(Suppl 1):65–71.CrossRefPubMedPubMedCentral

34.

Patel PM, Sanchez-Melendez SN, Nambudiri VE. A narrative review of studies assessing the quality of life in patients with generalized pustular psoriasis. Exp Dermatol. 2023. https://doi.org/10.1111/exd.14787.CrossRefPubMed

Title: Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice
Authors: Anna Balato
Francesca Ambrogio
Martina Burlando
Carlo Giovanni Carrera
Andrea Chiricozzi
Maria Esposito
Stefano Piaserico
Miriam Teoli
Paolo Gisondi
Publication date: 02-12-2023
Publisher: Springer Healthcare
Keywords: Generalized Pustular Psoriasis
Plaque Psoriasis
Published in: Dermatology and Therapy / Issue 1/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-023-01073-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey

Biologics in Prevention of Psoriasis to Psoriatic Arthritis Transition: The Need of Prospective Analyses and Stratification According to Time-Related Risk Factors

Evaluation of a Novel Microfocused Ultrasound with Three‐Dimensional Digital Imaging for Facial Tightening: A Prospective, Randomized, Controlled Trial

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials